April 13, 2017 6:35pm

 

Weathered sentiment … a fresh high

There is a lot of hindsight that applies to the current sector environment.

 

Pre-open indications:  3 hits and 2 miss <made money by selling into strength, safety is my middle name>

 

Out and about: Biostage (BSTG) share pricing withers on the vine with stakeholder consequences by inaction and inattention consequences …

 

I answer one question, in which company should investors commit and keep their money

Get breaking news and the sector’s daily interpretation in your email …

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

Henry’omics:

From the pre-open’s investor’s letter title, “Cell therapy’s biggest losers – lately, shareholders! As they leave, trial subjects will be left out of a research study which will get smaller and less powered.”

  • Reiterating, “Managements need to mount an offensive to lure back the disaffected, coddle the currents shareholders and then prove that they can deliver on share pricing or they will have lost the hearts and minds of investors

As I have stated, “Also, don’t be dependent on some of those PR firms who shouldn’t be rowing on your boat as they provide the same old hype rhetoric and old fustian BS to only increase the wail of the shrills>”

  • Sector equities closed felt some tail wind on Thursday after being lower on Wednesday as investors traders focused on the oversold.

 

The U.S. stock market is closed Friday due to a holiday.

 

 

What analytics were there today and why it was important in today’s sector outcomes?

… The DOW closed down -138.61 or -0.67% to 20,453.25 while the NASDAQ closed down -31.01 or -0.53% to 5805.15 …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 16 …

· after Wednesday’s 15.75 post Tuesday’s 15.14, +7% higher having been as high as +10% …following Monday’s 13.6 after Friday’s 12.75 following last Thursday’s 12.1

…The iShares Russell 2000 (IWM) indicated a negative -0.12% at the pre-open was and closed DOWN -1.36%;

… The iShares NASDAQ Biotechnology (IBB) did NOT indicate at the pre-open and closed UP +0.10%.

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was positive with an A/DL of 24/17 and 2 flats;

·         The mid-day was positive with an A/DL of 23/15 and 5 flats;

·         The close was positive with an A/DL of 22/17 and 4 flats;

 

… Decliners ranged from -0.27% <BCLI> to -8.43% <OPXA> in 17 equities;

… Gainers ranged from +0.21% <CUR> to +14.20% <VSTM> in 22 equities;

 

 

Pre-open indications:  3 hits and 2 miss:

  • Applied Genetic Technologies (AGTC) closed up +$0.10 – hit;
  • Bellicum Pharma (BLCM) closed up +$0.44 – hit;
  • Juno therapeutics (JUNO) closed up +$0.31 – miss;
  • Kite Pharma (KITE) closed up +$3.05 – miss;
  • Verastem (VSTM) closed up +$0.23 – hit;

 

 

Out and about:

Biostage (BSTG) drops -$0.0114 or -3.70% to a wholesome $0.296 …

It is “Lord of the Flies” everyday … dysfunction leaks from every window in this company …

Where the BOD as the share price is slithers?  

What is in store for “ruined” investors? April 1, the stock was $0.34, March 1 - $0.37, February 1 - $0.74 and January 3’s $0.87 following December 1’s $1.08.

What is this CEO doing other than running down the share pricing, alienating stakeholders and pandering to some executive’s self-interests?

Where is the peer reviewed publication that has been promised for 7 or was is 8 months (sarcasm)!

 I think it is an insult to shareholders that a “president” has been appointed <for a 28 person company> after all the damage, he has caused and enacted to those who have “left” in the past two years.

It has been stated that the “supposed” publication has been delayed due to an unnamed “territorial” temper and might I indulge that fact that the “proof of concept” is NOT quite the evidence needed to facilitate an IND filing?

My response is check the SOP – oh, I forgot – there is NONE as the “president” has changed it again as he has done every … 10 to 20 minutes.

The real question can the surgeries be reproducible and NOT VIOLATE Nanofiber’s patents who has published a collaborative peer reviewed publication with Mayo Clinic while BSTG has NOT!

And what other damage can be laid at his feet … <one word>?

This BOD is derelict … a NEW management team is NEEDED!!!

There is also, a NASDAQ issue (11/18/16 compliance letter received) – roll it over again or reverse spit?

The red flag is flying … or a white flag for surrendering to an extreme dilution of a warrant exercise, a proportionate reverse or as I believe a BANKRUPTCY …

NOTICE a NEW SEC filing as of April 13th … http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11528991&type=HTML&symbol=BSTG&companyName=Biostage+Inc.&formType=POS+AM&dateFiled=2017-04-13&cik=0001563665

21 million shares plus warrants offered -- I have NO words as Q1/15 the stock was trading at $4.43 and Q3/16, the stock was $1.22 when the current CEO took his position …

Lets also NOT forget a ... 13.97% or 1.85 M share short position and ratio of the 34.1 M share float ...

 

What a legacy … everyone has an opinion – maybe you have one too?

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.